StockData

Burning Rock Biotech vs Fulgent Genetics

BNR and FLGT side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BNR and FLGT compare

Fulgent Genetics grew revenue faster over the last twelve months (4.7% versus 4.6% for Burning Rock Biotech).

Burning Rock Biotech keeps more of each dollar of sales as profit, with a net margin of −10.3% compared with −27.5% at Fulgent Genetics.

Fulgent Genetics scores higher on the StockData Score (8 against 5 for Burning Rock Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBNRFLGT
Size and price
Market cap–$679M
Share price$13.29$24.66
Change, 1 year8.8%−15.2%
Change, 5 years−92.2%−73.8%
Beta (5Y)1.730.89
Employees6671,300
StockData Score
Total score58 (better)
Valuation score03 (better)
Growth score1 (better)0
Performance score2 (better)1
Health score24 (better)
Dividend score00
Valuation
P/S–2.1×
P/B–0.7×
FCF yield–−0.21%
Fair value–$46.08
Margin of safety–46.5%
Growth
Revenue growth (TTM)4.6%4.7% (better)
Revenue growth, 5Y average4.6% (better)−5.2%
Profitability
Gross margin74.7% (better)33.8%
Operating margin−10.2% (better)−39.2%
Net margin−10.3% (better)−27.5%
FCF margin−6.2%−0.42% (better)
Return on equity−9.9%−8.6% (better)
Return on invested capital−72.5%−12.0% (better)
Financial health
Debt / equity0.000.00 (better)
Interest coverage–−1307.9×
Current ratio2.995.34 (better)
Altman Z-score–5.18
Piotroski F-score5 (better)4
Dividends and buybacks
Buyback yield–9.5%
Shareholder yield–9.5%
Ownership
Held by institutions1.8%57.0%
Held by insiders19.0%39.5%
Insider net buying, 12 months$11.6M (better)−$286K
Short interest, % of float–12.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.